statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
read more...

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for...

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Investors considering a purchase of Nurix Therapeutics Inc (NRIX) stock, but cautious about paying the going market price of 15.09/share, might benefit from considering selling puts among the...

Commit To Purchase Nurix Therapeutics At $10, Earn 18.3% Annualized Using Options

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees

Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Presentation highlights Nurix's innovation and leadership in targeted protein modulation, including ligase inhibition Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas...

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

This indicator may be signaling that NRIX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Nurix Therapeutics (NRIX, $13.1) entered Downtrend as Momentum indicator drops below 0 level on Mar 15, 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX  Get Free Report) traded down 3.8% during mid-day trading on Friday . The company traded as low as $13.49 and last traded at $13.50. 522,814 shares were...

Nurix Therapeutics (NASDAQ:NRIX) Trading Down 3.8%

Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the studySAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics...

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Volume	465,539.00
52-Wk High	$18.12
52-Wk Low	$4.22

NRIX Nurix Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals